Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451152 | 1.00 | LCK (0.54) | LCKRAB9AMAPTNPC1OPRK1 | |
| SCHEMBL25303610 | 0.87 | LCK (0.56) | LCKRAB9AMAPTNPC1OPRK1 | |
| SCHEMBL31114499 | 0.85 | LCK (0.56) | LCKRAB9AMAPTHTTKMT2A | |
| SCHEMBL25303576 | 0.85 | LCK (0.56) | LCKRAB9AMAPTHTTKMT2A | |
| SCHEMBL25300411 | 0.84 | LCK (0.50) | LCKRAB9ANPC1KMT2A | |
| SCHEMBL31114623 | 0.84 | LCK (0.50) | LCKRAB9ANPC1KMT2A | |
| SCHEMBL31114701 | 0.83 | LCK (0.54) | LCKRAB9AMAPTKMT2APOLB | |
| SCHEMBL25255289 | 0.83 | LCK (0.54) | LCKRAB9AMAPTKMT2APOLB | |
| SCHEMBL31114633 | 0.82 | DYRK1A (0.51) | LCK | |
| SCHEMBL25303404 | 0.82 | DYRK1A (0.51) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | LCK 1173/4885RAB9A 2727/4885MAPT 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.